UroGen Pharma (URGN) Tops Q3 EPS by 18c

UroGen Pharma (NASDAQ: URGN) reported Q3 EPS of ($1.31), $0.18 better than the analyst estimate of ($1.49). Revenue for the quarter came in at $3.46 million versus the consensus estimate of $3.34 million.

“We are excited to see the continued interest and uptake of Jelmyto for patients with low-grade upper tract urothelial cancer in the first full quarter of launch, with a steady increase in new patients and providers as well as positive reimbursement trends. Additionally, we are pleased with the feedback we are receiving from urologists who see this treatment as a novel solution to avoid surgical intervention with a positive impact on patient outcomes,” said Liz Barrett, President and Chief Executive Officer of UroGen. “With our second product candidate, UGN-102, soon to enter a pivotal trial and a recently enhanced management team, we look forward to continuing our mission of bringing novel solutions to patients with specialty cancers and urologic diseases.”

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49